Samsung Biologics bags $1.24bn CDMO contract with Asia-based pharma firm
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), has signed its largest-ever contract, valued at USD 1.24 billion, with an undisclosed Asia-based pharmaceutical company. The agreement, the largest single-client contract in the company’s history, extends until December 2037, with production set at the biomanufacturing hub in Songdo, South Korea. Contract Milestones […]